Long-Acting Insulin Glargine to Hit Drug Market
Posted: Jan 18 2016

Each month the FDA approves new medications, and below is a highlight of the most relevant new approvals and/or drugs which have the potential to impact your prescription plan. While the medications below have been evaluated and approved by the FDA, they may not enter the marketplace for several weeks or months.

New Generic Approvals
Drug Name Uses/Treatment Pricing Information Other Information
Fesoterodine Fumarate (Toviaz) Treatment of overactive bladder with symptoms of urinary incontinence, urgency, and frequency Pricing information not yet available
  • Step therapy exists for this category of drugs
Imatinib Mesylate (Gleevec) Oral specialty drug used for specific cancer treatments Pricing information not yet available
  • Anticipated launch date is 02/01/2016
  • Will be rolled into MedTrak’s split-fill program for certain oral anti-cancer agents
  • Will be subject to MedTrak’s PA process for specialty medications

New Brand Approvals
Drug Name Uses/Treatment Pricing Information Other Information
Basaglar Long-acting insulin glargine for the treatment of type 1 and type 2 diabetes Pricing information not yet available
  • Similar to Sanofi’s Lantus
  • Anticipated market entry not until December 2016
  • Non-formulary upon market entry
Zurampic Treatment of hyperuricemia associated with gout Pricing information not yet available
  • Indicated as add-on therapy only and not monotherapy
  • Non-formulary upon market entry

New Specialty Approvals
Drug Name Uses/Treatment Pricing Information Other Information
Alecensa Treatment of metastatic non-small cell lung cancer (NSCLC) Cost approximately $14,800/month
  • Indicated to be used as 2nd line therapy for NSCLC
  • Will be subject to MedTrak’s PA process for specialty medications
  • Non-formulary upon market entry
Bendeka Treatment of chronic lymphocytic leukemia (CLL) & non-Hodgkin’s lymphoma (NHL) Pricing information not yet available
  • Indicated first line for CLL
  • Indicated to be used as 2nd line for NHL
  • Will be subject to MedTrak’s PA process for specialty medications
  • Non-formulary upon market entry
Uptravi For the treatment of pulmonary arterial hypertension (PAH) Pricing information not yet available
  • Other similar oral treatments already commercially available
  • Will be subject to MedTrak’s PA process for specialty medications.
  • Non-formulary upon market entry